Abstract
Introduction
Despite the widespread use of bisphosphonates, its effects on normal bone microarchitecture of the proximal femur are still poorly studied. The purpose of this study was to determine the effects of long-term high-dose treatment of alendronate on microstructure and bone mineral density of cancellous, cortical compact and subchondral compact bone of the femoral head and neck region in normal adult male rabbits.
Materials and methods
Thirty-two adult, male rabbits were randomized into and were treated with either alendronate or placebo for 6 and 12 months. Micro-QCT measurements were taken in the (1) trabecular region, (2) cortical region of the femoral neck and (3) the subchondral region of the femoral head.
Results
In the trabecular region of the femoral head, alendronate treatment significantly increased vBMD at 6 and 12 months (+21.0%, p < 0.05 and +26.8%, p < 0.05, respectively) and BVF (29.6%, p < 0.05 and 35.6%, p < 0.05, respectively) with significantly altered bone microarchitecture when compared with their placebo group; 6- and 12-month alendronate treatment significantly increased the vBMD and thickness and decreased the porosity of the subchondral bone in the femoral head.
Conclusion
High-dose alendronate treatment led to significant and differential changes in bone microarchitecture in trabecular, cortical and subchondral bone of the proximal femur of adult male rabbits.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00402-010-1116-1/MediaObjects/402_2010_1116_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00402-010-1116-1/MediaObjects/402_2010_1116_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00402-010-1116-1/MediaObjects/402_2010_1116_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00402-010-1116-1/MediaObjects/402_2010_1116_Fig4_HTML.gif)
Similar content being viewed by others
References
Orwoll ES (2006) Osteoporosis in men. Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. ASBMR, Washington, DC, pp 290–293
Melton LJ 3rd (1988) Epidemiology of Fractures. In: Riggs BL, Melton LJ 3rd (eds) Osteoporosis: etiology, diagnosis and management. Raven Press, New York
Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P (2007) Bisphosphonates in cancer therapy. Cancer Lett 257(1):16–35
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352
Black DM, DE Thompson, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349(13):1216–1226
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3):320–323
Watts NBR, Smith C, Li Z, Eastell R, Pack S, Lindsay R (2000) BMD changes explains only a fraction of the observed fracture risk reduction in risedronate-treated patients. Osteoporos Int 11(Suppl 2)(546):S203
Miller PD, McClung M (1996) Prediction of fracture risk. I: Bone density. Am J Med Sci 312(6):257–259
Fratzl P, Gupta HS, Paschalis EP, Roschger P (2004) Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem 14:2115–2123
Roschger P, Paschalis EP, Fratzl P, Klaushofer K (2008) Bone mineralization density distribution in health and disease. Bone 42(3):456–466
(2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795
Rodan G, Reszka A, Golub E, Rizzoli R (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20(8):1291–1300
Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29(2):185–191
Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L et al (2005) Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 36(1):150–158
Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22(1):149–157
Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28(5):524–531
Mosekilde L, Thomsen JS, Mackey MS, Phipps RJ (2000) Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 27(5):639–645
Pataki A, Muller K, Green JR, Ma YF, Li QN, Jee WS (1997) Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 249(4):458–468
Kippo K, Hannuniemi R, Isaksson P, Lauren L, Osterman T, Peng Z et al (1998) Clodronate prevents osteopenia and loss of trabecular connectivity in estrogen-deficient rats. J Bone Miner Res 13(2):287–296
Kobayashi S, Shimizu T, Mehdi R, Nawata M, Kojima S, Tsutsumimoto T et al (1999) Advantages of concurrent use of anabolic and antiresorptive agents over single use of these agents in increasing trabecular bone volume, connectivity, and biomechanical competence of rat vertebrae. Bone 25(6):703–712
Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y et al (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18(3):512–520
Ding M, Day JS, Burr DB, Mashiba T, Hirano T, Weinans H et al (2003) Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif Tissue Int 72(6):737–744
McCreadie BR, Goulet RW, Feldkamp LA, Goldstein SA (2001) Hierarchical structure of bone and micro-computed tomography. Adv Exp Med Biol 496:67–83
Barou O, Valentin D, Vico L, Tirode C, Barbier A, Alexandre C et al (2002) High-resolution three-dimensional micro-computed tomography detects bone loss and changes in trabecular architecture early: comparison with DEXA and bone histomorphometry in a rat model of disuse osteoporosis. Invest Radiol 37(1):40–46
Ding M, Odgaard A, Hvid I (2003) Changes in the three-dimensional microstructure of human tibial cancellous bone in early osteoarthritis. J Bone Joint Surg Br 85(6):906–912
Batiste DL, Kirkley A, Laverty S, Thain LM, Spouge AR, Gati JS et al (2004) High-resolution MRI and micro-CT in an ex vivo rabbit anterior cruciate ligament transection model of osteoarthritis. Osteoarthritis Cartilage 12(8):614–626
Wachsmuth L, Engelke K (2004) High-resolution imaging of osteoarthritis using microcomputed tomography. Methods Mol Med 101:231–248
Hofstaetter JG, Wang J, Yan J, Glimcher MJ (2006) Changes in bone microarchitecture and bone mineral density following experimental osteonecrosis of the hip in rabbits. Cells Tissues Organs 184(3–4):138–147
Thompson DD, Seedor JG, Quartuccio H, Solomon H, Fioravanti C, Davidson J et al (1992) The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 7(8):951–960
Thompson DD, Simmons HA, Pirie CM, Ke HZ (1995) FDA guidelines and animal models for osteoporosis. Bone 17(4 Suppl):125S–133S
Mosekilde L (1995) Assessing bone quality–animal models in preclinical osteoporosis research. Bone 17(4 Suppl):343S–352S
Rodgers JB, Monier-Faugere MC, Malluche H (1993) Animal models for the study of bone loss after cessation of ovarian function. Bone 14(3):369–377
Kimmel DB (2001) Animal models for in vivo experimentation in osteoporosis research. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 29–47
Gilsanz V, Roe TF, Gibbens DT, Schulz EE, Carlson ME, Gonzalez O et al (1988) Effect of sex steroids on peak bone density of growing rabbits. Am J Physiol 255(4 Pt 1):E416–E421
Rao DR, Sunki GR, Johnson WM, Chen CP (1977) Postnatal Growth of New Zealand White Rabbit (Oryctolagus cuniculus). J Anim Sci 44:1021–1025
Hofstaetter JG, Wang J, Yan J, Glimcher MJ (2008) The effects of alendronate in the treatment of experimental osteonecrosis of the hip in adult rabbits. Osteoarthritis Cartilage
Peter C, Rodan GA (1999) Preclinical safety profile of alendronate. Int J Clin Pract Suppl 101:3–8
Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104(1):83–93
Otsu N (1979) A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cyber 9:62–66
Sawka AM, Thabane L, Papaioannou A, Gafni A, Hanley DA, Adachi JD (2005) A systematic review of the effect of alendronate on bone mineral density in men. J Clin Densitom 8(1):7–13
Grynpas MD, Alpert B, Katz I, Lieberman I, Pritzker KP (1991) Subchondral bone in osteoarthritis. Calcif Tissue Int 49(1):20–26
Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J et al (2004) The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50(4):1193–1206
Feik SA, Thomas CD, Clement JG (1997) Age-related changes in cortical porosity of the midshaft of the human femur. J Anat 191(Pt 3):407–416
Bell KL, Loveridge N, Power J, Garrahan N, Stanton M, Lunt M et al (1999) Structure of the femoral neck in hip fracture: cortical bone loss in the inferoanterior to superoposterior axis. J Bone Miner Res 14(1):111–119
Ding M, Hvid I (2000) Quantification of age-related changes in the structure model type and trabecular thickness of human tibial cancellous bone. Bone 26(3):291–295
Holzer G, Skrbensky G, Holzer L, Pichl W (2008) Hip fractures and the contribution of cortical versus trabecular bone to femoral neck stability. J Bone Miner Res
Cooper D, Turinsky A, Sensen C, Hallgrimsson B (2007) Effect of voxel size on 3D micro-CT analysis of cortical bone porosity. Calcif Tissue Int 80(3):211–219
Currey JD (1990) Physical characteristics affecting the tensile failure properties of compact bone. J Biomech 23(8):837–844
Conflict of interest statement
All authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was performed at the Laboratory for Skeletal Disorders and Rehabilitation, Department of Orthopedic Surgery, Children’s Hospital and Harvard Medical School.
Rights and permissions
About this article
Cite this article
Hofstaetter, J.G., Wang, J., Hofstaetter, S.G. et al. The effects of high-dose, long-term alendronate treatment on microarchitecture and bone mineral density of compact and trabecular bone in the proximal femur of adult male rabbits. Arch Orthop Trauma Surg 130, 937–944 (2010). https://doi.org/10.1007/s00402-010-1116-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00402-010-1116-1